Published: Guidance, quality standards and advice
Showing 1 to 4 of 4
Title | Reference number | Published | Last updated |
---|---|---|---|
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 | TA257 | ||
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | ||
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | ||
Sickle cell disease: managing acute painful episodes in hospital | CG143 |